PreciseDx
Healthcare technology
AI-powered digital pathology and oncology diagnostics
Private; latest disclosed financing was an $11 mil
PreciseDx is a privately held oncology diagnostics company using AI-powered digital pathology to analyze tissue morphology and produce cancer-risk insights. Its proprietary Morphology Feature Array® is used with image analysis to support diagnostic and prognostic assessment. The company’s flagship product, PreciseBreast, is intended for breast cancer risk assessment; in November 2024 the company reported New York State Department of Health approval and an early access program with initial commercial testing. PreciseDx announced plans to prepare for a broader commercial launch in 2026. These are company-reported capabilities and plans, not an independent assessment of clinical performance or market leadership.
Company Details
- Website
- precisedx.ai
- Headquarters
- New York, New York, United States
- Founded
- 2020
- Funding
- Over $43 million reported by the company after its June 2025 funding announcement; the announcement
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring